CLRB - CIK 0001279704
The table below shows Cellectar Biosciences, Inc.'s balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $13.20M | $23.29M | $9.56M | $19.87M | $35.70M | $57.17M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $14.04M |
| $24.25M |
| $10.45M |
| $20.53M |
| $36.57M |
| $57.94M |
| Property, plant & equipment | $549.40K | $757.12K | $1.09M | $418.64K | $344.49K | $355.98K |
| Goodwill | - | - | - | - | - | - |
| Total assets | $14.98M | $25.47M | $12.08M | $21.59M | $37.20M | $58.66M |
| Accounts payable | $1.44M | $4.11M | $5.62M | $2.56M | $1.42M | $1.43M |
| Total current liabilities | $4.75M | $9.39M | $25.36M | $5.53M | $3.99M | $3.56M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $5.06M | $9.80M | $13.43M | $6.08M | $4.16M | $3.86M |
| Retained earnings | -$269.13M | -$247.34M | -$202.76M | -$179.50M | -$126.78M | -$126.78M |
| Total equity | $8.54M | $14.29M | -$15.16M | $15.51M | $33.05M | $54.79M |